User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial.

Primary tabs

Demeestere, Isabelle Brice, Pauline Peccatori, Fedro A Kentos, Alain Gaillard, Isabelle Van Den Neste, Eric [UCL] Englert, Yvon

Approximately 20% of patients in both groups exhibited POF after 1 year of follow-up. Triptorelin was not associated with a significant decreased risk of POF in young patients treated for lymphoma but may provide protection of the ovarian reserve.

Document type Article de périodique (Journal article)
Access type Accès restreint
Publication date 2013
Language Anglais
Journal information "Journal of clinical oncology : official journal of the American Society of Clinical Oncology" - Vol. 31, no. 7, p. 903-909 (2013)
Peer reviewed yes
issn 0732-183X
e-issn 1527-7755
Affiliation UCL - Autre
MESH Subject Adult ; Hodgkin Disease ; Humans ; Luteolytic Agents ; Lymphoma ; Lymphoma, Non-Hodgkin ; Middle Aged ; Norethindrone ; Premenopause ; Primary Ovarian Insufficiency ; Prospective Studies ; Antineoplastic Combined Chemotherapy Protocols ; Time Factors ; Treatment Failure ; Triptorelin Pamoate ; Biological Markers ; Drug Therapy, Combination ; Estradiol ; Female ; Follicle Stimulating Hormone ; Follow-Up Studies ; Gonadotropin-Releasing Hormone
Links
Bibliographic reference Demeestere, Isabelle ; Brice, Pauline ; Peccatori, Fedro A ; Kentos, Alain ; Gaillard, Isabelle ; et. al. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial.. In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 31, no. 7, p. 903-909 (2013)
Permanent URL http://hdl.handle.net/2078.1/132472